Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ACM-010
- Development stage
- Preclinical
- Lead developer
- ACM Biolabs
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics
01
Overview
ACM-010 is a prophylactic vaccine developed by ACM Biolabs Pte Ltd. It functions as a Toll-like receptor (TLR) agonist, aiming to stimulate the immune system. The drug is currently in preclinical development for its potential use in treating respiratory tract infections.
Beyond the preview
Go deeper on ACM-010.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ACM-010.